Agnosía

Seventy-Five Percent of Color Blind People Experience Challenges at Work, EnChroma Study Finds

Retrieved on: 
Monday, July 26, 2021
Optical, Professional services, Health, Human resources, Vision, Color vision, Nervous system, Sensory systems, Ophthalmology, Agnosía, Color blindness, Visual impairment, Enchroma, Glasses, Color, Visual perception

View the full release here: https://www.businesswire.com/news/home/20210726005726/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210726005726/en/
    View of color wires as they appear to someone with color vision deficiency and to someone with standard color vision.
  • From April to May 2021, 810 color blind people responded to an EnChroma survey measuring the effect of their condition on the job, with 688 relaying anecdotes from their work experiences.
  • Color blind people are just as successful and productive as any employee, but they can use a hand to reduce the everyday nuisances and obstacles they experience related to color in the workplace.
  • Consider making reasonable workplace accommodation assistive tools available to color blind employees, like EnChroma glasses for color blindness.

AGTC to Present at American Optometric Association’s Optometry’s Meeting  

Retrieved on: 
Tuesday, June 22, 2021
Branches of biology, Vision, Biology, Channelopathies, Ion channels, Achromatopsia, Agnosía, Visual perception, Visual system, Applied Genetic Technologies Corporation, Cyclic nucleotide gated channel beta 3, Cyclic nucleotide-gated channel alpha 3

Dr. Lin also will also lead three continuing education courses related to gene therapy and IRDs.

Key Points: 
  • Dr. Lin also will also lead three continuing education courses related to gene therapy and IRDs.
  • AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases.
  • AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3).
  • AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.

Nutra Pharma Announces Private Label Expansion of their Over-The-Counter Pain Relievers

Retrieved on: 
Friday, June 4, 2021
Pain, Palliative care, Agnosía, Analgesic, Opioids, Pain management, Nervous system, Branches of biology, Symptoms and signs

Nutra Pharma is announcing the first private label agreement in expansion of their line of over-the-counter pain relievers and anti-inflammatory drugs

Key Points: 
  • The first private label distributor contract has been executed with sales expected to start within the next 4-6 weeks.
  • "This will allow increased sales to Nutra Pharma by expanding our customer base into markets not currently available to us.
  • Nyloxin is a safe, non-narcotic, and non-addictive Homeopathic pain reliever for the relief of pain without impairing cognitive function.
  • Nyloxin is available as an oral spray for systemic pain and as a topical gel for targeted pain management.

The Children’s Eye Foundation of AAPOS Debuts THE CURIOUS EYE: World’s First Interactive Storybook to Help Screen for Color Vision Deficiency

Retrieved on: 
Monday, May 17, 2021
Children, Entertainment, Books, Health, Preschool, Consumer, Primary, Secondary, Optical, Education, Vision, Nervous system, Organ systems, Color vision, Agnosía, Color blindness, Visual impairment, Color

b"The Children\xe2\x80\x99s Eye Foundation of AAPOS today unveiled the world\xe2\x80\x99s first interactive children\xe2\x80\x99s book to help screen for color vision deficiency (CVD), commonly known as color blindness.

Key Points: 
  • b"The Children\xe2\x80\x99s Eye Foundation of AAPOS today unveiled the world\xe2\x80\x99s first interactive children\xe2\x80\x99s book to help screen for color vision deficiency (CVD), commonly known as color blindness.
  • View the full release here: https://www.businesswire.com/news/home/20210517005159/en/\nThe Children\xe2\x80\x99s Eye Foundation of AAPOS today unveiled the world\xe2\x80\x99s first interactive children\xe2\x80\x99s book to help screen for color vision deficiency (CVD), commonly known as color blindness.
  • \xe2\x80\x9cIt is a playful yet practical screening tool to help parents, educators, and eyecare professionals identify children who may have color vision deficiency early.
  • Follow the Children\xe2\x80\x99s Eye Foundation of AAPOS on Facebook , Instagram , and Twitter .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210517005159/en/\n"

Concentric Analgesics Announces Podium Presentation of Vocacapsaicin Clinical Data at 46th Annual ASRA Meeting

Retrieved on: 
Tuesday, May 11, 2021
Research, Surgery, Hospitals, FDA, Clinical trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Pain, Opioids, Agnosía, Analgesic, Osteoarthritis, Organ systems, Branches of biology, Clinical medicine

\xe2\x80\x9cI am pleased to be a part of this exciting research program.\xe2\x80\x9d\nSam Teichman, MD, Head of Clinical Development at Concentric Analgesics said, \xe2\x80\x9cWe are delighted that the first scientific presentation of our important new TKA data will be at ASRA.

Key Points: 
  • \xe2\x80\x9cI am pleased to be a part of this exciting research program.\xe2\x80\x9d\nSam Teichman, MD, Head of Clinical Development at Concentric Analgesics said, \xe2\x80\x9cWe are delighted that the first scientific presentation of our important new TKA data will be at ASRA.
  • A 2016 US News & World Report revealed that one in 10 patients report becoming addicted or dependent on opioids following surgery.
  • Concentric has two additional active programs for indications with significant unmet medical need: osteoarthritis pain and chronic refractory pain.
  • For more information, please visit the company\xe2\x80\x99s website at: www.concentricanalgesics.com .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210511005293/en/\n'

Global Analgesics Market Report 2020: COVID-19 Implications and Growth - Forecast to 2023, 2025 & 2030 - ResearchAndMarkets.com

Retrieved on: 
Monday, February 15, 2021
Biotechnology, Pharmaceutical, Health, Pain, Agnosía, Analgesic, Opioids

The "Analgesics Global Market Report 2020-30: COVID-19 Implications and Growth" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Analgesics Global Market Report 2020-30: COVID-19 Implications and Growth" report has been added to ResearchAndMarkets.com's offering.
  • The analgesics market has been geographically segmented into North America, Western Europe, APAC, Eastern Europe, South America and Middle East & Africa.
  • The North American market is the largest market for Analgesics and is expected to continue to be the largest market during the forecast period.
  • The growth of analgesics market is restricted by the increasing use of biologics for the treatment of inflammatory and neuropathic pain.

MeiraGTx Announces AAV-CNGA3 Granted Fast Track Designation by U.S. FDA for Treatment of Achromatopsia

Retrieved on: 
Tuesday, January 26, 2021
Vision, Nervous system, Sensory systems, Achromatopsia, Agnosía, Channelopathies, Visual perception, Visual system, Cyclic nucleotide-gated channel alpha 3, Orphan drug, Fast track, European Medicines Agency

MeiraGTx is currently conducting an open-label, dose-escalation Phase 1/2 clinical trial of AAV-CNGA3 in patients with ACHM due to mutations in the CNGA3 gene.

Key Points: 
  • MeiraGTx is currently conducting an open-label, dose-escalation Phase 1/2 clinical trial of AAV-CNGA3 in patients with ACHM due to mutations in the CNGA3 gene.
  • Fast Track designation enables the company to have early and frequent communication with the FDA throughout the drug development and review process, with the potential for faster drug approval and patient access.
  • AAV-CNGA3 has already been granted Orphan Drug designation by the FDA and European Medicines Agency (EMA).
  • This is the third Fast Track designation MeiraGTx has received for its inherited retinal disease product candidates, having previously received Fast Track designation for AAV-RPGR and AAV-CNGB3, as well as having received PRIME designation for AAV-RPGR and AAV-CNGB3 from the EMA.

AGTC to Participate in the H.C. Wainwright BioConnect 2021 Conference

Retrieved on: 
Wednesday, January 6, 2021
Vision, Branches of biology, Nervous system, Ion channels, Channelopathies, Achromatopsia, Agnosía, Visual perception, Visual system, Cyclic nucleotide gated channel beta 3, Cyclic nucleotide-gated channel alpha 3, Retinitis pigmentosa

The fireside chat will be available to view on-demand beginning Monday, January 11, 2021 at 6:00AM ET through the entirety of the conference and available by visiting http://ir.agtc.com/events-and-presentations .

Key Points: 
  • The fireside chat will be available to view on-demand beginning Monday, January 11, 2021 at 6:00AM ET through the entirety of the conference and available by visiting http://ir.agtc.com/events-and-presentations .
  • AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases.
  • AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 & ACHM CNGA3).
  • AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.

ViewSonic Partners with TÜV SÜD to Develop the Testing of a Color Blindness Feature in Monitors

Retrieved on: 
Thursday, December 17, 2020
Color vision, Vision, Nervous system, Sensory systems, Agnosía, Color blindness, ViewSonic, Computer monitor, Visual impairment, Color

, a leading global provider of visual solutions, and TV SD , the globally acclaimed safety and quality expert organization, announced the world's first TV SD testing of a color blindness feature in monitors and have set a new test methodfor the electronics industry.

Key Points: 
  • , a leading global provider of visual solutions, and TV SD , the globally acclaimed safety and quality expert organization, announced the world's first TV SD testing of a color blindness feature in monitors and have set a new test methodfor the electronics industry.
  • ViewSonic'scolor blindness feature consists of two modes - a color filter mode for color vision deficiency (CVD) users anda simulation mode for creators to deliver a color blindness friendly experience.
  • TV SD conducted rigorous tests on ViewSonic's color blindness features, including color recognition confirmation, color filter software and color simulation with the aim of establishing a high-quality testing method for the industry."
  • TV SD and ViewSonic have taken the lead to define a new set of testing methods for the compatibility of monitors with color vision deficiency features.

ViewSonic Partners with TÜV SÜD to Develop the Testing of a Color Blindness Feature in Monitors

Retrieved on: 
Thursday, December 17, 2020
Color vision, Vision, Nervous system, Sensory systems, Agnosía, Color blindness, ViewSonic, Computer monitor, Visual impairment, Color

, a leading global provider of visual solutions, and TV SD , the globally acclaimed safety and quality expert organization, announced the world's first TV SD testing of a color blindness feature in monitors and have set a new test methodfor the electronics industry.

Key Points: 
  • , a leading global provider of visual solutions, and TV SD , the globally acclaimed safety and quality expert organization, announced the world's first TV SD testing of a color blindness feature in monitors and have set a new test methodfor the electronics industry.
  • ViewSonic'scolor blindness feature consists of two modes - a color filter mode for color vision deficiency (CVD) users anda simulation mode for creators to deliver a color blindness friendly experience.
  • TV SD conducted rigorous tests on ViewSonic's color blindness features, including color recognition confirmation, color filter software and color simulation with the aim of establishing a high-quality testing method for the industry."
  • TV SD and ViewSonic have taken the lead to define a new set of testing methods for the compatibility of monitors with color vision deficiency features.